Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 501–600 of 1,001
Xiong, Y., Greschik, H., Johansson, C., Seifert, L., Bacher, J., Park, K., Babault, N., Martini, M. L., Fagan, V., Li, F., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00522 · Cited by 35
Self-citationMoreno–Yruela, C., Bæk, M., Vrsanova, A.-E., Schulte, C., Maric, H. M., & Olsen, C. A. (2021) · Nature Communications · doi:10.1038/s41467-020-20250-9 · Cited by 36
Zhang, K., Liu, Z., Yao, Y., Qiu, Y., Li, F., Chen, D., Hamilton, D. J., Li, Z., & Jiang, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02161 · Cited by 35
Duan, Y., Zhang, S., Shi, X., Jin, L., Yu, T., Song, Y., & Guan, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113588 · Cited by 37
Renu, S., & Ravikumar, V. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.07.015 · Cited by 36
Gang, W., JunJie, W., HongMing, T., HuaFu, Z., & Wang, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s82282 · Cited by 37
“More recently, the development of effective SIRT1-specific antagonists or inhibitors of SIRT family proteins and the need for potent and selective inhibitors, particularly those of SIRT1, remain to be fulfilled.(67) Among”
BackgroundRetractedLee, J., Yang, B., Lindahl, A. J., Damaschke, N., Boersma, M., Huang, W., Corey, E., Jarrard, D. F., & Denu, J. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01035 · Cited by 35
“are being developed offering new options for cancer treatment (43).”
BackgroundTargeting protein methylation: from chemical tools to precision medicines
Dilworth, D., & Baršytė-Lovejoy, D. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03147-9 · Cited by 38
“Consequently, there is significant interest in the pharmacological modulation of proteins that write, read, and erase methyl marks [13, 14].”
BackgroundXu, J., Wang, Q., Leung, E. L., Li, Y., Fan, X., Wu, Q., Yao, X., & Liu, L. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0694-8 · Cited by 35
An updated patent review of BRD4 degraders
Ma, Z., Zhang, C., Bolinger, A. A., & Zhou, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2400166 · Cited by 35
Design of small molecule epigenetic modulators
Pachaiyappan, B., & Woster, P. M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.001 · Cited by 35
Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy
Ghosh, A. K., Rai, R., Flevaris, P., & Vaughan, D. E. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25699 · Cited by 35
“Epigenetic modifications of lysine residues in chromatin histone tails and transcription factors, via acetylation or deacetylation, alters gene expression by regulating DNA–histone interaction and affecting the activity of nuclear transcription factors (Arrowsmith et al., 2012).”
BackgroundCR2Cancer: a database for chromatin regulators in human cancer
Ru, B., Sun, J., Tong, Y., Wong, C. N., Chandra, A., Tang, A. T. S., Chow, L. K.-Y., Wun, W. L., Levitskaya, Z., & Zhang, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx877 · Cited by 40
“In addition, the reversible nature of epigenetic modifications provides plausible prevention and treatment options for cancer therapy through targeting CRs (16,17).”
BackgroundBhushan, B., Erdmann, A., Zhang, Y., Belle, R., Johannson, C., Oppermann, U. C. T., Hopkinson, R. J., Schofield, C. J., & Kawamura, A. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.030 · Cited by 34
Schiedel, M., Moroglu, M., Ascough, D. M. H., Chamberlain, A. E. R., Kamps, J. J. A. G., Sekirnik, A. R., & Conway, S. J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812164 · Cited by 37
Biggar, K. K., Charih, F., Liu, H., Ruiz‐Blanco, Y. B., Stalker, L., Chopra, A., Connolly, J., Adhikary, H., Frensemier, K., Hoekstra, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107896 · Cited by 37
Epigenome-metabolome-microbiome axis in health and IBD
Amatullah, H., & Jeffrey, K. L. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.08.005 · Cited by 38
“This has made proteins that regulate the epigenome some of the most promising and intently pursued targets in drug discovery today [6,7]; yet, a critical gap exists in our understanding of altered epigenetic enzymes or chromatin that result in immune disorders, including IBD.”
BackgroundMaternal obesity as a risk factor for developing diabetes in offspring: An epigenetic point of view
Lecoutre, S., Maqdasy, S., & Breton, C. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.366 · Cited by 36
Guo, Z., Zhang, Z., Yang, H., Cao, D., Xu, X., Zheng, X., Chen, D., Wang, Q., Li, Y., Li, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00297 · Cited by 36
Protein Acetylation Going Viral: Implications in Antiviral Immunity and Viral Infection
Xue, M., Feng, T., Chen, Z., Yan, Y., Chen, Z., & Dai, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911308 · Cited by 33
Analysis of the subcellular localization of the human histone methyltransferase SETDB1
Tachibana, K., Gotoh, E., Kawamata, N., Ishimoto, K., Uchihara, Y., Iwanari, H., Sugiyama, A., Kawamura, T., Mochizuki, Y., Tanaka, T., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.065 · Cited by 34
England, K. S., Tumber, A., Krojer, T. J., Scozzafava, G., Ng, S. S., Daniel, M., Szykowska, A., Che, K., von Delft, F., Burgess-Brown, N., et al. (2014) · MedChemComm · doi:10.1039/c4md00291a · Cited by 33
Koh, X., Joy, J. K., Poulsen, A., Li, R., Tan, Y. T. F., Shim, Y., Min, J., Wu, L., Ngo, A., Peng, J., et al. (2014) · Biochemical Journal · doi:10.1042/bj20140374 · Cited by 38
“While not much is known about the role of H3K18 methylation, di-methylated H3K9 and H4K20 are well-characterized histone marks associated with transcriptionally silent or repressed genes, while H3K4me3 is a hallmark of transcriptionally active genes (15).”
BackgroundStructure–activity relationship studies of SETD8 inhibitors
Ma, A., Yu, W., Xiong, Y., Butler, K. V., Brown, P. J., & Jin, J. J. (2014) · MedChemComm · doi:10.1039/c4md00317a · Cited by 34
Blancafort, P., Jin, J. J., & Frye, S. V. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080697 · Cited by 41
“lases (Klose et al., 2006; Arrowsmith et al., 2012), and the”
BackgroundVukovič, S., Brennan, P. E., & Huggins, D. J. (2016) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/28/34/344007 · Cited by 33
Ren, K., Zhang, W. K., Chen, X., Ma, Y., Dai, Y., Fan, Y., Hou, Y., Tan, R. X., & Li, E. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005950 · Cited by 34
Talukdar, A., Mukherjee, A., & Bhattacharya, D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01208 · Cited by 34
Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery
Lee, W. H. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002164 · Cited by 35
“However, despite there being more than 400 proteins known to be involved in epigenetic regulation [14], as of 2010, only one target family, histone deacetylases (HDACs), comprised of more than 20 proteins, had been targeted by cell active inhibitors in the public domain.”
BackgroundHuston, A., Arrowsmith, C. H., Knapp, S., & Schapira, M. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1871 · Cited by 35
Self-citationRobertson, J. C., Hurley, N. C., Tortorici, M., Ciossani, G., Borrello, M. T., Vellore, N. A., Ganesan, A., Mattevi, A., & Baron, R. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003158 · Cited by 33
Poncet-Montange, G., Zhan, Y., Bardenhagen, J., Petrocchi, A., Leo, E., Shi, X., Lee, G. R., Leonard, P. G., Geck, M., Cardozo, M. G., et al. (2014) · Biochemical Journal · doi:10.1042/bj20140933 · Cited by 35
Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin
Yue, F., Li, W., Zou, J., Chen, Q., Xu, G., Huang, H. W., Xu, Z., Zhang, S., Gallinari, P., Wang, F., et al. (2015) · Aging · doi:10.18632/aging.100818 · Cited by 37
“HDAC-mediated histone deacetylation is a key epigenetic modification that has attracted enormous attention since histone deacetylases emerged as a druggable class of enzymes [21].”
BackgroundChemical probes for methyl lysine reader domains
James, L. I., & Frye, S. V. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.004 · Cited by 33
Roatsch, M., Hoffmann, I., Abboud, M. I., Hancock, R. L., Tarhonskaya, H., Hsu, K., Wilkins, S. E., Yeh, T.-L., Lippl, K., Serrer, K., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00289 · Cited by 34
Chen, J., Yeh, K., Yang, Y.-M., Chang, J., Lee, H.-E., & Hung, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0513-z · Cited by 33
Understanding the Complexity of Epigenetic Target Space
Pande, V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01507 · Cited by 40
Methyllysine binding domains: Structural insight and small molecule probe development
Teske, K. A., & Hadden, M. K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.047 · Cited by 32
“Royal proteins are further classified into subfamilies based on additional structural features that flank the central fold and guide their selectivity for a particular methylation mark [7,41,42].”
BackgroundEpigenome alterations in aortic valve stenosis and its related left ventricular hypertrophy
Gošev, I., Zeljko, M., Đurić, Ž., Nikolić, I., Gošev, M., Ivčević, S., Bešić, D., Legčević, Z., & Paić, F. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0406-7 · Cited by 36
Muneer, I., Qamar, M. T. U., Tusleem, K., Rauf, S. A., Hussain, H. M. J., & Siddiqi, A. R. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000727 · Cited by 32
Li, Z., Xiao, S.-H., Yang, Y., Chen, C., Lu, T., Chen, Z., Jiang, H., Chen, S., Luo, C., & Zhou, B. N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01784 · Cited by 32
Yun, F., Cheng, C., Ullah, S., & Yuan, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112322 · Cited by 35
Histone modifications, DNA methylation, and the epigenetic code of alcohol use disorder
Bohnsack, J. P., & Pandey, S. C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.08.005 · Cited by 36
“HATs demonstrate a degree of histone lysine specificity, for example Gcn5 and PCAF demonstrate selectivity for H3 over H4 while P300 and CBP broadly acetylate all four histone isoforms (Roth et al., 2001).”
BackgroundInfluentialEpigenetic modifications of Klotho expression in kidney diseases
Xia, J., & Cao, W. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02044-8 · Cited by 34
A Chemical Tool for In Vitro and In Vivo Precipitation of Lysine Methyltransferase G9a
Konze, K. D., Pattenden, S. G., Liu, F., Baršytė-Lovejoy, D., Li, F., Simon, J. M., Davis, I. J., Vedadi, M., & Jin, J. J. (2014) · ChemMedChem · doi:10.1002/cmdc.201300450 · Cited by 32
Goda, S., Isagawa, T., Chikaoka, Y., Kawamura, T., & Aburatani, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.492595 · Cited by 36
Lenoci, A., Tomassi, S., Conte, M., Benedetti, R., Rodríguez, V., Carradori, S., Secci, D., Castellano, S., Sbardella, G., Filetici, P., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300536 · Cited by 33
Chen, S., Li, L., Chen, Y., Hu, J., Liu, J., Liu, J. Y.-C., Liu, R., Zhang, Y., Meng, F., Zhu, K., et al. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00738 · Cited by 33
Bromodomain inhibitors regulate the C9ORF72 locus in ALS
Zeier, Z. R., Esanov, R., Belle, K. C., Volmar, C., Johnstone, A. L., Halley, P., DeRosa, B. A., Khoury, N., van Blitterswijk, M., Rademakers, R., et al. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.06.017 · Cited by 36
“There have nowbeen remarkable advancements in developing small molecules that target classes of epigenetic proteins other thanHDACs or DNMTs (Arrowsmith et al., 2012).”
BackgroundThe Epigenome and Its Role in Diabetes
Waki, H., Yamauchi, T., & Kadowaki, T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0328-x · Cited by 33
“Histone acetylation neutralizes the positive charge on lysine, thus reducing the affinity of the histone tail that protrudes from the nucleosome core of DNA, allowing chromatin to form a more relaxed structure closely associated with gene activation [11].”
BackgroundInfluentialSmall molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases
Wang, Z., & Patel, D. J. (2013) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583513000085 · Cited by 36
“…(HDACs) were among the first epigenetic regulatory enzymes to be targeted for drug design (Minucci & Pelicci, 2006 ; Szyf, 2009), with several of these inhibitors approved by the Food and Drug Administration (FDA) for clinical use in hematological malignancies (Arrowsmith et al. 2012).”
BackgroundIntegrating Epigenomics into the Understanding of Biomedical Insight
Han, Y., & He, X. (2016) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s38427 · Cited by 32
“20,21 They work jointly with DNA, histone, and nonhistone proteins to form a complex interaction network in regulating chromatin accessibility for transcription.”
BackgroundIFN-γ Influences Epithelial Antiviral Responses via Histone Methylation of the RIG-I Promoter
Spalluto, C. M., Singhania, A., Cellura, D., Woelk, C. H., Sánchez-Elsner, T., Staples, K. J., & Wilkinson, T. M. A. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0392oc · Cited by 31
Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer
Roche, J., Gemmill, R. M., & Drabkin, H. A. (2017) · Cancers · doi:10.3390/cancers9070072 · Cited by 36
“These modifications are further recognized by proteins called “readers” that recruit various adapters for regulation of gene expression [31] (Table 1).”
BackgroundRNA-modifying enzymes and their function in a chromatin context
Tzelepis, K., Rausch, O., & Kouzarides, T. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0312-0 · Cited by 32
Williams, D. E., & Andersen, R. J. (2019) · Natural Product Reports · doi:10.1039/c9np00054b · Cited by 33
Wang, X., Lewis, D. A., Wang, G., Meng, T., Zhou, S., Zhu, Y., Hu, D., Gao, S., & Zhang, G. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200053 · Cited by 31
The role and prospect of lysine‐specific demethylases in cancer chemoresistance
Song, Y., Yang, G., Ma, D., Wang, W., & Leung, C. (2023) · Medicinal Research Reviews · doi:10.1002/med.21955 · Cited by 32
“Up to now, more than 30 KDMs have been found.(31) According to sequence homology and structural similarity, KDMs can be further grouped into eight subfamilies (KDM1‐8s).”
BackgroundAdvancements in the delivery of epigenetic drugs
Cramer, S. A., Adjei, I. M., & Labhasetwar, V. D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1021678 · Cited by 35
“Efforts are being made to identify these targets and to develop inhibitors/ activators [99].”
BackgroundAlterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications
Silverman, B., & Shi, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122138 · Cited by 36
“HAT inhibitors range from less specific natural substances to covalently modified isothiazolones [67].”
BackgroundEpigenetic Regulation of Hepatic Lipogenesis: Role in Hepatosteatosis and Diabetes
Viscarra, J. A., & Sul, H. S. (2020) · Diabetes · doi:10.2337/dbi18-0032 · Cited by 38
A chemical space odyssey of inhibitors of histone deacetylases and bromodomains
Prieto-Martínez, F. D., Gortari, E. F., Méndez‐Lucio, O., & Medina‐Franco, J. L. (2016) · RSC Advances · doi:10.1039/c6ra07224k · Cited by 30
BPTF Depletion Enhances T-cell–Mediated Antitumor Immunity
Mayes, K., Alkhatib, S. G., Peterson, K., Alhazmi, A., Song, C., Chan, V., Blevins, T. L., Roberts, M., Dumur, C. I., Wang, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3125 · Cited by 32
“19 gamma through the STAT1 and IRF-1 transcription factors (44,45), and are repressed in tumor cells by DNA methylation and histone deacetylation (46-48).”
BackgroundA Fluorescence‐Lifetime‐Based Binding Assay for Class IIa Histone Deacetylases
Meyners, C., Mertens, M., Wessig, P., & Meyer‐Almes, F. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201605140 · Cited by 30
Structural and Functional Basis of C-Methylation of Coumarin Scaffolds by NovO
Sadler, J. C., Chung, C., Mosley, J. E., Burley, G. A., & Humphreys, L. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01053 · Cited by 30
Chemical Control of a CRISPR-Cas9 Acetyltransferase
Shrimp, J. H., Grose, C., Widmeyer, S. R. T., Thorpe, A. L., Jadhav, A., & Meier, J. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00883 · Cited by 31
Therapeutic targeting of immune checkpoints with small molecule inhibitors.
Smith, W. M., Purvis, I. J., Bomstad, C. N., Labak, C. M., Velpula, K. K., Tsung, A. J., Regan, J. N., Venkataraman, S., Vibhakar, R., & Asuthkar, S. (2019) · Europe PMC (PubMed Central) · Cited by 36
Dynamic methylation of histone H3K18 in differentiating Theileria parasites
Cheeseman, K., Jannot, G., Lourenço, N., Villares, M., Berthelet, J., Calegari-Silva, T., Hamroune, J., Letourneur, F., Rodrigues‐Lima, F., & Weitzman, J. B. (2021) · Nature Communications · doi:10.1038/s41467-021-23477-2 · Cited by 37
Methyltransferase inhibitors for modulation of the epigenome and beyond
Schapira, M., & Arrowsmith, C. H. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.05.030 · Cited by 33
Self-citationEpigenetic Mechanisms in Psychiatric Diseases and Epigenetic Therapy
Karslı-Çeppioğlu, S. (2016) · Drug Development Research · doi:10.1002/ddr.21340 · Cited by 33
“HATs are classified in five families [Marmorstein and Trievel, 2009; Arrowsmith et al., 2012]; the GNAT family; the MYST family; the p300/CBP family; the SRC family and the TAFII250 family.”
BackgroundDrugging the Schistosome Zinc-Dependent HDACs: Current Progress and Future Perspectives
Marek, M., Oliveira, G., Pierce, R. J., Jung, M., Sippl, W., & Romier, C. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.25 · Cited by 38
Li, X., Wu, Y., Tian, G., Jiang, Y., Liu, Z., Meng, X., Bao, X., Feng, L., Sun, H., Deng, H., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02738 · Cited by 31
Tough, D. F., Lewis, H. D., Rioja, I., Lindon, M. J., & Prinjha, R. K. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12848 · Cited by 31
“As is the case for the epigenetic writers and erasers, large families of readers able to recognize different modified amino acids have been identified and recently reviewed (Arrowsmith et al., 2012).”
BackgroundJennings, L. E., Measures, A. R., Wilson, B. G., & Conway, S. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.197 · Cited by 32
Binding Kinetics versus Affinities in BRD4 Inhibition
Kuang, M., Zhou, J., Wang, L., Liu, Z., Guo, J., & Wu, R. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00265 · Cited by 30
Synthesis and biological evaluation of largazole zinc-binding group analogs
Kim, B., Ratnayake, R., Lee, H., Shi, G., Zeller, S. L., Li, C., Luesch, H., & Hong, J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.071 · Cited by 30
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II)
Lenstra, D. C., Temimi, A. H. K. A., & Mecinović, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.02.043 · Cited by 29
Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”
Dzobo, K. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0206 · Cited by 29
“These mutations cause different cancer cell characteristics ranging from uncontrolled cellular growth, cancer cell heterogeneity, drug resistance, and metastasis (Arrowsmith et al., 2012; Pfister and Ashworth, 2017).”
Rodrı́guez, Y., Gerona‐Navarro, G., Osman, R., & Zhou, M. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25818 · Cited by 30
“Studies of histone biology show that specific proteins add PTM marks (writers), recognize marks (readers), and remove marks (erasers).(3,4) The proteins associated with acetylated lysine (AcK) are well described: histone acetyltranferases (HATs) add the acetyl group, histone deacetylases remove the acetyl group, and b…”
BackgroundEpigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives
Faldoni, F. L. C., Rainho, C. A., & Rogatto, S. R. (2020) · Cells · doi:10.3390/cells9051164 · Cited by 37
“Permissive histone marks, including lysine acetylation and methylation (such as H3K9me1, H3K27me1, H3K36me3, H3K79me3, H3K4me1-3, and H4K20me1) are associated with chromatin accessibility, while lysine methylation is also a repressive mark and involved in the transcriptional silencing (for example, H3K9me3, H3K27me3,…”
BackgroundDiscovery of a Potent and Selective Covalent p300/CBP Inhibitor
Mastracchio, A., Lai, C., DiGiammarino, E. L., Ready, D. B., Lasko, L. M., Bromberg, K. D., McClellan, W. J., Montgomery, D., Manaves, V., Shaw, B., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00654 · Cited by 29
Fu, Y., Zhang, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113853 · Cited by 30
Epigenetics: the fine-tuner in inflammatory bowel disease?
Stylianou, E. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328360bd12 · Cited by 37
VDR hypermethylation and HIV-induced T cell loss
Chandel, N., Husain, M., Goel, H., Salhan, D., Lan, X., Malhotra, A., McGowan, J. P., & Singhal, P. C. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812383 · Cited by 30
Process of Fragment-Based Lead Discovery—A Perspective from NMR
Ma, R., Wang, P., Wu, J., & Ruan, K. (2016) · Molecules · doi:10.3390/molecules21070854 · Cited by 31
“Most recently, epigenetic targets have become a new frontier in drug discovery [31], including anti-cancer and anti-inflammation inhibitors that block the recognition of acetylated histones via bromodomains and induce profound chromatin biology [32–37].”
BackgroundChromatin targeting drugs in cancer and immunity
Prinjha, R. K., & Tarakhovsky, A. (2013) · Genes & Development · doi:10.1101/gad.221895.113 · Cited by 30
Choi, S. K., Hong, S. H., Kim, H. S., Shin, C. Y., Nam, S. W., Choi, W. S., Han, J., & You, J. S. (2015) · Oncology Reports · doi:10.3892/or.2015.4410 · Cited by 32
Tucker, G. T., Desilva, B. S., Dressman, J., Ito, M., Kumamoto, T., Mager, D., Mahler, H., der Zee, A. H. M., Pauletti, G. M., Sasaki, H., et al. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.12.001 · Cited by 29
Sekirnik, A. R., Hewings, D. S., Theodoulou, N. H., Jursins, L., Lewendon, K. R., Jennings, L. E., Rooney, T. P. C., Heightman, T. D., & Conway, S. J. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201602908 · Cited by 28
Oksala, N., Seppälä, I., Rahikainen, R., Mäkelä, K.-M., Raitoharju, E., Illig, T., Klopp, N., Kholová, I., Laaksonen, R., Karhunen, P. J., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.02.014 · Cited by 28
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative
Zhang, J., Chen, P., Zhu, P., Zheng, P., Wang, T., Wang, L., Xu, C., Zhou, J., & Zhang, H. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103817 · Cited by 29
Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
Lu, H., Dai, W., & He, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s288500 · Cited by 31
“However, this field remains challenging, since the enzymes have a broad substrate specificity and deacetylate many proteins that are not related to epigenetic regulation.(136) Although these data indicate that histone acetylation and methylation may play a key role in altered gene expression during DKD, it is more nec…”
BackgroundThomas, X. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.722618 · Cited by 28
Kim, J., Kim, E., Koun, S., Ham, H.-J., Rhee, M., Kim, M.-J., & Huh, T. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0053 · Cited by 30
“Due to their significance in regulating genetic program during development and diseases, recent efforts were directed to identify specific factors that mediate this process (Arrowsmith et al., 2012; Cayuso Mas et al., 2011; Kim et al., 2012a; 2012b).”
BackgroundInfluentialImran, A., Lee, J., Go, A., Choi, G., & Lee, K. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.025 · Cited by 29
Self-citationAn Overview of HDAC Inhibitors and their Synthetic Routes
Peng, X., Liao, G., Sun, P., Yu, Z., & Chen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190227221507 · Cited by 31
Sun, W., von Meyenn, F., Peleg‐Raibstein, D., & Wolfrum, C. (2019) · Advanced Science · doi:10.1002/advs.201900275 · Cited by 37
BRD4: an effective target for organ fibrosis
Wei, Q., Gan, C., Sun, M., Xie, Y., Liu, H., Xue, T., Deng, C., Mo, C., & Ye, T. (2024) · Biomarker Research · doi:10.1186/s40364-024-00641-6 · Cited by 34
Developing epigenetic diagnostics and therapeutics for brain disorders
Qureshi, I., & Mehler, M. F. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.003 · Cited by 31
Mechanism and Kinetics of Acetyl-Lysine Binding to Bromodomains
Magno, A., Steiner, S., & Caflisch, A. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct400361k · Cited by 32
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.